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Introduction
Seven transmembrane G protein coupled receptors (GPCR) are the most profligate cell surface receptors in biology [1, 2] . GPCRs mediate a plethora of physiological and pathophysiological cellular responses and in the latter setting are the targets of multiple therapeutic agents with prominent examples being angiotensin II receptor blockers and beta adrenoceptor blockers for the treatment of cardiovascular disease and beta agonists for the treatment of respiratory diseases [3] . GPCR signalling involves transactivation independent pathways [4] passing from the agonist mediated conformational changes in the receptor, activation of G proteins and signal propagation via a plethora of downstream mechanisms including activation of adenylate cyclase and the generation of cAMP, activation of phospholipase C-β and the generation of IP 3 and diacylglycerol and activation of Rho-GTPase and activation of ROCK [1, 5] . GPCRs can also signal through the utilization of the β-arrestin molecule [6, 7] .
Two decades ago it was described that GPCRs could transactivate cell surface tyrosine kinase receptors. The initial finding described transactivation of the Epidermal Growth Factor (EGF) family leading to the (auto) phosphorylation and activation of the tyrosine kinase receptor itself and generation of one of the immediate downstream products being the activated Mitogen-Activated Protein (MAP) kinase, phosphoErk (pErk) [8, 9] . The transactivation of receptor tyrosine kinases, typically cell growth receptors, greatly expanded the repertoire of responses attributable to GPCRs. Over time this paradigm of tyrosine kinase receptor transactivation has been extended to involve multiple GPCRs and multiple tyrosine kinase receptors [10] [11] [12] [13] .
More recently the paradigm of GPCR mediated kinase receptor transactivation has been expanded to include transactivation of a serine/threonine kinase receptor, specifically the receptor for Transforming Growth Factor (TGF)-β being the TGF-β Type I receptor
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(TGFBR1) [14] [15] [16] . In this latter pathway, agonist mediated activation of, for example, the thrombin receptor, protease activated receptor-1 (PAR-1), leads to transactivation of TGFBR1 and the generation of the immediate downstream product of the receptor being carboxy terminal phosphorated Smad2 (pSmad2C) [15] .
Thrombin is a GPCR agonist which has been identified in atherosclerotic plaque both as the protein and critically as the enzymatically active serine protease [17] . Thrombin stimulation of human vascular smooth muscle cells (VSMCs) leads to the enhanced synthesis of the matrix molecules termed proteoglycans. In the context of thrombin mediated stimulation of proteoglycan synthesis in VSMCs, we recently reported that thrombin stimulation leads to an increase in radiosulfate incorporation into secreted proteoglycans which is approximately equally and totally blocked by antagonists of EGF and TGF-β receptors and concluded that all of the signalling is via transactivation of these two kinase receptors concomitantly [16] . Further analysis of the effects of thrombin revealed that the increase in the length of the GAG chains on the biglycan core proteins (which are hyperelongated in thrombin treated cells) also occurred via transactivation of these two kinase receptors. The specific evidence of the two kinase receptor signalling pathways in this response is that thrombin mediates increased levels of pErk and pSmad2C in these cells and these responses are blocked by PAR-1 antagonists [15] .
The signalling pathways that mediate the expression of biglycan core protein expression and the multiple enzymes that mediate GAG synthesis and hyperelongation have some similarities but also some distinct features [18] [19] [20] [21] [22] . For example, the cytosolic serine/threonine kinase, Akt, normally associated with cell survival, plays a role in the stimulation of biglycan expression however it plays no discernible role in GAG hyperelongation [20, 21] . Recent work has shed light on the specific enzymes which mediate the synthesis of chondroitin/dermatan sulfate GAG chains on proteoglycans [23] [24] [25] [26] and the
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6 hormone and growth factor signalling pathways that lead to the hyperelongation of the GAG chains [14] [15] [16] . The growth factor and hormone signalling pathways that control the expression of these enzymes are important because there is considerable evidence that GAG hyperelongation is a critical early step in the development of human atherosclerosis [27] .
GAG synthesis involves the combination of more than one GAG synthesizing enzyme for the elongation of the chondroitin/dermatan sulphate GAG chains [28] . Two golgi enzymes namely the chondroitin 4-O sulphotransferase-1 (C4ST-1) and chondroitin Nacetylegalactosaminoglycan-2 play a critical role in the regulation of the GAG chain length in vitro [26] . Anggraeni et al [29] showed an increase in the synthesis of chondroitin/dermatan sulfate GAG chains during the development of atherosclerosis in a mouse model which was accompanied by an increase in the expression of the two GAG synthesizing enzymes. As such, the signalling pathways leading to the expression of these GAG synthesizing enzymes represent potential therapeutic targets for the treatment of atherosclerosis.
We have thus explored the role of kinase receptor transactivation pathways in the signalling that mediates thrombin stimulated gene expression of chondroitin synthase-1 (ChSy-1) and C4ST-1. In this manuscript we describe that for both outputs, the signalling involves transactivation of EGFR and TGFBR1 and the combined effect of these signalling pathways accounts for all of the mechanistic readout. These data indicate that GPCR transactivation of tyrosine and serine/threonine kinase pathways is associated with context specific responses being both the increase expression of core proteins and GAG synthesizing genes. The signlaing patwhays involve phosphorylated Erk and also linker region phosphorylated Smad2. These data point towards potential therapeutic targets for atherogenesis, leading to the development of a specific inhibitor of GPCR transactivation dependent signalling that would mitigate CS/DS GAG hyperelongation and serve as a treatment of atherosclerosis.
Materials and Methods
Materials
Dulbecco's Modified Eagle medium (DMEM) (0 and 25mM glucose), Trypsinversene, antibiotics (10,000 U/ml penicillin, 10,000 μg/ml streptomycin) were purchased from GIBCO, (Grand Island, USA 
Solution, Ammonium Persulfate(APS) and Quantity One imagine software were from BioRad Laboratories (CA, USA).
Cell Culture
Primary cultures of human vascular smooth muscle cells (VSMCs) were obtained from discarded sections of saphenous veins from patients undergoing coronary artery bypass grafting at the Alfred Hospital; the acquisition of the vessels was approved by the Alfred Hospital Ethics Committee [30] . Cells were grown in DMEM (5mM glucose, 10% FBS and 1% antibiotics at 37⁰C in 5% CO 2 ) VSMCs were seeded in 60 mm dishes and 6 well-plates. Cells were grown to confluence then rendered quiescent by serum deprivation for 48 h.
Assessing mRNA gene expression
The mRNA level of the GAG enzymes was determined by real-time polymerase chain reaction (RT-PCR). Total RNA was isolated from VSMCs treated as described. Total RNA was extracted from 5×10 5 cells using RNeasy Mini kit (Qiagen) according to the manufacturers' instructions. RNA purity was checked by spectrophotometry (260/280nm) using a Nanodrop2000 spectrophotometer (Thermo Fisher Scientific). First strand cDNA was synthesized from 1µg RNA using Quantitect reverse transcriptase kit (Qiagen) according to the manufacturers' instructions. Quantitate RT-PCR was performed using Qiagen Rotor Gene Q and QuantiFast SYBR Green PCR Master Mix kit (Qiagen). RT-PCR used human specific
Chondrotin-4-sulfotransferase-1 (C4ST-1) and Chondroitin synthase-1(ChSy-1) primer sequences. The data was normalised to 18S as the house keeping gene. Relative expression of mRNA levels was quantified using comparative delta delta Ct method.
Western Blotting
Total cell lysates (40µg of protein) were resolved by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) on 10% gels and transferred onto
polyvinylidene difluoride membrances (PVDF). Membranes were blocked with 5% bovine serum albumin (BSA) and incubates with antipSmad2(Ser245/250/255),anti-pSmad2(Ser465/467), anti-phosphoEGFR(Tyr1068), antipErk1/2(Thr202/Tyr204) rabbit monoclonal antibody followed by HRP-anti-rabbit IgG and ECL detection. Blots were imaged using the Bio-Rad gel documentation system and densitometry analysis was performed with Quantity One imaging software.
Statistical Analysis
Data was normalised and is shown as the mean ± standard error of the mean of three independent experiments performed in triplicate, unless stated otherwise. A one-way ANOVA was used to calculate statistical significance of normalised data as stated. Results
were considered significant when the probability was less than 0.05 (*p < 0.05) and 0.01 (**p < 0.01).
Results
Thrombin through its receptor PAR-1 leads to the expression of GAG biosynthesizing enzymes
To explore the pathway of PAR-1 transactivation leading to GAG chain elongation we investigated the expression of GAG biosynthesizing enzymes, specifically chondroitin 4-sulfotransferase-1 (C4ST-1) and chondroitin synthase-1 (ChSy-1) we asked the question whether or not the transactivation of PAR-1 to EGFR or TGFBR1 leads to gene expression of GAG synthesizing enzymes.
VSMCs were treated with thrombin and mRNA expression of the C4ST-1 and ChSy-1 was measured at time points 0.5, 1, 2, 4 and 6 h ( Figure 1 ). Thrombin (10units/ml) caused a time-dependent increase in mRNA expression of C4ST-1 ( Figure 1A ) and ChSy-1 ( Figure   1B ). At 2 h post-thrombin stimulation, a 2-fold increase (p < 0.05) in the mRNA expression
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10 of C4ST-1 was detected ( Figure 1A ), which reached a peak of 4-fold (p < 0.01) at 6 h ( Figure   1A ). A similar response was observed for the mRNA expression of ChSy-1 where thrombin stimulated a 2.5-fold increase at 4 h (p < 0.05) ( Figure 1B ) and reached a peak of 3.5-fold (p < 0.01) at 6 h ( Figure 1B ).
We have demonstrated previously that in VSMCs thrombin through the PAR-1 receptor leads to GAG chain elongation and an increase in the expression of biglycan core protein [15] . We then explored the role of PAR-1 on the mRNA expression of GAG synthesizing enzymes C4ST-1 and Chsy-1 using PAR-1 antagonist SCH79797. Thrombin treatment (10 units/ml, 6h) increased mRNA expression of C4ST-1 by 3-fold (p<0.01) ( Figure 1C ). The PAR-1 antagonist SCH79797, had a dose-dependent inhibition in the mRNA expression of C4ST-1, where the half maximal inhibitory concentration for SCH79797 was approximately 3μM and at 10µM, the expression level was completely inhibited (p<0.01) ( Figure 1C ). Results were similar for the effects of thrombin on the mRNA expression level of ChSy-1 ( Figure 1D ). ChSy-1 mRNA expression was increased to1.8-fold (p<0.05) following thrombin stimulation ( Figure 1D ) and in the presence of SCH79797 was inhibited in a dose-dependent manner. The data indicates that the PAR-1 receptor is involved in thrombin stimulated mRNA expression of C4ST-1 and ChSy-1 in these cells.
Mutliple agonists stimulate the expression of GAG biosynthesizing enzymes which is inhibited by their respective antagonists
To investigate the presence of the relevant receptors, pathways and responses, VSMCs were treated with growth factors thrombin, TGF-β and EGF in the presence and absence of their respective receptor antagonists SCH79797, SB431542 and AG1478.
Thrombin increased the mRNA expression of C4ST-1 by nearly 3-fold (p<0.01) (Figure 2A ).
In the presence of SCH79797 (30µM) the thrombin mediated mRNA expression of C4ST-1 To evaluate the role of the PTKR, EGFR, in thrombin-mediated expression C4ST-1
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and ChSy-1 mRNA expression, we employed the EGFR antagonist AG1478 [31] (Figure 3 ).
AG1478 had a dose dependent inhibitory effect on thrombin mediated mRNA expression of both C4ST-1 and ChSy-1 ( Figure 3C and D) . Thrombin stimulsted a 2.5-fold increase in the mRNA expression of C4ST-1 (p<0.01) ( Figure 3C ). In the presence of AG1478 the inhibition was concentration dependent with a half maximal inhibitory effect at approximately 1μM and a maximal inhibitory effect of 100% occurred at 10μM (p<0.01) ( Figure 3C ). Similarly thrombin mediated mRNA expression of ChSy-1 showed a 2-fold increase (p<0.01) ( Figure   3D ). In the presence of AG1478 there was a dose dependent inhibition of the thrombin mediated mRNA expression. The half maximal inhibitory effect was approximately 0.5μM and a maximal inhibitory effect of 100% occurred at 10μM (p<0.01) ( Figure 3D ). These results indicate that thrombin can also transactivate the EGFR to generate the mRNA expression of C4ST-1 and ChSy-1.
The S/TK and PTK pathways combine in thrombin mediated expression of GAG biosynthesizin enzymes
To investigate if thrombin can transactivate EGFR and TGFBR1 to cooperate in generating increased mRNA expression of C4ST-1 and ChSy-1, the EGFR and TGFBR1
inhibitors AG1478 (5µM) and SB431542 (3µM) respectively were used in VSMCS treated with thrombin (10units/ml). Thrombin treated VMSCs showed an increased mRNA expression of C4ST-1 to almost 3-fold (p<0.01) ( Figure 4A ). In the presence of AG1478 the mRNA expression was completely inhibited (p<0.01) ( Figure 4A ). SB431542 showed a 50% inhibition of the thrombin mediated mRNA expression of C4ST-1 (p<0.01) ( Figure 4A ). In
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13 the presence of both of the receptor antagonists, AG1478 and SB431542, the mRNA expression was completley inhibited (p<0.01) ( Figure 4A ). For ChSy-1 expression thrombin increased the mRNA expression of ChSy-1 to 2-fold ( Figure 4D ). In the presence of AG1478 (p<0.05) and SB431542 (p<0.01) ( Figure 4D ) the mRNA expression for ChSy-1 was completely inhibited.
To further explore the role of PAR-1 we used thombin receptor activator (TRAP), the synthetic peptide that specifically activates the PAR-1 receptor. TRAP treated VSMCs showed an increased mRNA expression of C4ST-1 to almost 2-fold (p<0.01)( Figure 4C ). The mRNA expression of C4ST-1 was inhibited by 80% in the presence of SB431542 (p<0.01)( Figure 4C ). Similarly AG1478 had a 50% inhibition of TRAP mediated mRNA expression of C4ST-1 (p<0.01). In the presence of both receptor antagonists it showed a combined inhibitory effect (p<0.01). TRAP increased the mRNA expression of ChSy-1 to 2.3-fold (p<0.01)( Figure 4F ). In the presence of AG1478 (p<0.01) and SB431542(p<0.01) the mRNA expression of ChSy-1 was inhibited by 80%. In the presence of both of the receptor antagonists, the mRNA expression showed a combined inhibitory effect representing total inhibition of the response (p<0.01) ( Figure 4F ).
To investigate whether or not the PTKR and S/TKR signalling pathways have a combined potentially independent effect in activating the mRNA expression of C4ST-1 and
ChSy-1 we investigated the responses to the direct agonists EGF (100nM) and TGF-β (2ng/ml) both individually and in combination. EGF and TGF-β treatment individually increased the mRNA expression of C4ST-1 to 2.3-(p<0.05) and 2.1-fold (p<0.05), respectively ( Figure 4B ). When the two agonists were combined there was an additive effect in the mRNA expression of C4ST-1 to almost 5-fold (p<0.01) ( Figure 4B ). We observed a very similar pattern when looking at the mRNA expression of ChSy-1. EGF and TGF-β increase the mRNA expression of ChSY-1 to 1.5-and 3.1-fold (p<0.01) respectively (Figure
14 4E). The two agonists showed an additive effect in the mRNA expression of ChSy-1 to almost 5-fold (p<0.01) ( Figure 4E ). This data shows that both EGF and TGF-β pathways are involved in the increase expression of C4ST-1 and ChSy-1 and the combined effect of stimulating both pathways produces an additive effect indicating that the pathways are at least to some extent independent.
The combined roles of the S/TK and PTK pathways on the phosphorylation of Erk and the Smad2 linker region
Having established the role of thrombin in activation of GAG gene expression we wished to explore the contribution of the relevant signalling pathways to the responses observed. Thus, to investigate the roles of PTKR and S/TKR signalling pathways on Erk1/2 ( Figure 5A ) and Smad2 linker region ( Figure 5B ) phosphorylation we used the respective agonists EGF and TGF-β and compared the results of that of thrombin treated cells.
Thrombin had a 2-fold increase in the phosphorylation of Erk1/2 ( Figure 5A ). EGF and TGF-β increased the phosphorylation of Erk1/2 to 6-(p<0.01) and 2-fold respectively ( Figure 5A ).
When EGF and TGF-β were combined Erk1/2 phosphorylation was increased by 6-fold (p<0.01) ( Figure 5A ). We observed a very similar pattern when looking at the phosphorylation of Smad2 in the linker region. Thrombin had a 2-fold (p<0.05) increase in Smad2 linker region phosphorylation ( Figure 5B ). EGF and TGF-β showed a 3.7-(p<0.01) and 2-fold (p<0.05) increase in the phosphorylation of Smad2 linker region, respectively ( Figure 5B ). When the two agonists where combined, Smad2 linker region phosphorylation showed a 3.7-fold (p<0.01) increase with a trend showing the signalling pathways were additive ( Figure 5B ). Thus, there is a correlation between the magnitude of the signalling response ( Figure 5 ) and the gene expression results (Figure 4 ).
Thrombin mediated Smad2 linker region phosphorylation is partially dependent on MMP shedding however phosphorylation of Smad2 in the carboxy terminal is not
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We have previously shown that the PTKR transactivation in VSMCs follows the well characterised MMP meditated triple-membrane bypass system of activation however the TGFBR1 transactivation is not dependent on membrane shedding of TGF-β ligands [16] . The transactivation of TGFBR1 by PAR-2 was demonstrated by Chung et al [32] which confirms our findings except that they found that transactivation of TGFBR1 to be dependent on
MMPs. Their experiments utilized a Smad linker region antibody (personal communication)
which produces a less clear outcome than the Smad carboxy terminal directed antibody the phosphorylation of which is a direct result of TGFBR1 activation whereas there are multiple pathways that meditae Smad linker region phosphorylation. We re-examined the role of [33] . As a control, we showed that GM6001 has no effect on the ability of TGF-β to stimulate linker region phosphorylation (pSmad2(Ser245/250/255)) ( Figure 6A lanes 7&8 ). VSMCs treated with thrombin showed an increase in the carboxy terminal phosphorylation of Smad2(Ser465/467) and GM6001 had no effect on this response which is consistent with our previous published data [16] . To confirm that PAR-1 mediated EGF receptor transactivation occurs through 
Discussion
The signalling pathways that control the processes that regulate the length of GAG chains on the proteoglycan, biglycan, represent a potential therapeutic target for the prevention of diseases, such as atherosclerosis, which depend upon the biglycan-dependent trapping of lipoproteins in tissues. We have been investigating the signalling pathways for the GPCR and serine protease agonist thrombin which is expressed in atherosclerotic plaques and is therefore a potential mediator of cardiovascular disease [17] . We have previously used the apparent size of biglycan molecules assessed as bands on an SDS-PAGE to study the pathways through which thrombin mediates GAG hyperelongation and we showed that all of the signalling for this hyperelongation response occurred through PAR-1 mediated transactivation of the EGFR and TGFBR1 [15, 16] . To move these studies to more precise investigations of the biochemical pathways controlling GAG hyperelongation and potentially more specific drug targets, we explored the mRNA expression of the range of genes potentially associated with the expression of the enzymes which mediate GAG elongation.
We found that, in human VSMCs treated with thrombin, following a short lag period, the expression of C4ST-1 and ChSy-1 were increased up to at least 6 hours with a peak increase of 3-4 fold. The increased expression of these genes correlates with the GAG elongation effect of thrombin [16] . Furthermore, the expression of C4ST-1 is increased in the atherosclerotic vessels from high fat fed LDL -/-mouse [29] suggesting that these genes mediate GAG elongation and hyperelongation in vivo. We then investigated the cellular signalling patwhays underlying the action of thrombin on C4ST-1 and ChSy-1 gene expression.
The thrombin-stimulated expression of C4ST-1 and ChSy-1 was blocked in a concentration-dependent manner and to a total inhibition of 100 per cent by the PAR-1 antagonist SCH79797 strongly suggesting that the response is mediated via PAR-1. We then and ChSy-1 mRNA expression was blocked strongly indicating that all of the signalling is through the (dual) kinase receptor transactivation pathways.
Chung et al. [32] recently demonstrated PAR-2 transactivation of a cell surface serine/threonine kinase receptor, TGFBR1, and they reported identical mechanisms to that occurring in their renal fibrosis model as in our VSMC model with the notable exception that they reported the process of transactivation of TGFBR1 to be dependent on MMPs whereas we reported that the process does not involve MMPs [16] . Samd linker region phosphorylation can occur via the TGF-β mediated activation of a plethora of serine/threonine kinases (or alternatively many other agonist-activated serine/threonine kinases) [33] whereas the response of carboxy terminal phosphorylation of Smad occurs only as a direct result of the kinase activity of TGFBR1 directed to Smad2 or Smad3 [33, 34] . To address the role of MMPs in PAR-1 mediated transactivation of serine/threonine kinase receptors we assessed the phosphorylation of Smad2 in both the linker region and the carboxy terminal. Thrombin stimulated the phosphorylation of Smad2 in both the linker region and the carboxy terminal domains but only the phosphorylation of the linker region phosphorylation was blocked by the board spectrum MMP inhibitor, GM6001, therefore indicating the role of MMPs in linker region but not carboxy terminal phosphorylation (Fig.   9 ). There are many pathways leading to linker region phosphorylation but only one pathway to carboxy terminal phosphorylation. Our results thus explain the findings of Chung et al.
[32]and confirms that MMPs are not involved in GPCR transactivation of TGFBR1
.
The results observed in these studies in human VSMCs of the thrombin stimulated expression of the mRNA for two of the genes associated with GAG hyperelongation are consistent with those we observed when studying functional or structural readout of the actual size of the biglycan molecules determined by SDS-PAGE [16] . In the studies based on biglycan bands we observed a partial role for each of the EGFR and TGFBR1 transactivation pathways and based on studies with pharmacological agents we concluded that all of the signalling was mediated via the two transactivation pathways [16] . In the present studies examining the expression of the mRNA of two genes associated with GAG hyperelongation we observed that each of the individual pathways, when assessed by the use of the relevant pharmacological antagonists appeared to be able to mediate almost 100 per cent of the response. Consistent with earlier data both pathways accounted for all of the signalling which reinforces the importance of the transactivation pathways in this response. We do not at the moment have an understanding of why the individual pathways of EGFR and TGFβR1
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19 mediate such a high proportion of the gene expression responses to thrombin. Importantly, we have previously reported that SB431548 does not block EGFR signalling and that AG1478 does not block TGFBR1 signalling [15] so there is no spillover of inhibitory activity from one pathway to another which could explain these results. In further related studies (unpublished) we have observed that TGFBR1 strongly and EGF weakly stimulates the mRNA expression for the core protein of biglycan and surprisingly thrombin does not stimulate the expression of biglycan. This data implies that there are interactions between these signalling pathways and more work is required to unravel this issue.
There is considerable evidence from in vitro, animal and human studies that hyperelongation of GAG chains on biglycan is associated with the early stages of atherosclerosis [35] . Ultimately, to establish causation, one would wish to analyse the size of biglycan molecules or their GAG chains an atherosclerotic model but this is technically exceedingly difficult and there are only two reports of this measurement [29, 36] . It is sometimes more practical to use a surrogate measures of a potential therapeutic target, in our case GAG hyperelongation. Thus, we have commenced studies of the expression of the genes which might represent the multitude of enzymes which mediate the synthesis of chondroitin sulfate/dermatan sulphate (CS/DS) GAG chains [37] [38] [39] [40] [41] [42] [43] . The mechanism of CS/DS GAG synthesis has not been fully elucidated but as many as 12 enzymes are involved being transferases to add monosaccharides moieties to the growing chains as well as sulfotransferases which add sulfate residues to the disaccharide units in the growing chain but may also be involved in the control of GAG length. We have been able to deduce by correlation that thrombin increases GAG hyperelongation and also increases the expression of two of the genes of interest, C4ST-1 and ChSy-1, but clearly further studies are required to establish the specific role of these enzymes in thrombin mediated GAG hyperelongation.
However, on the assumption that these agents are important in GAG synthesis and GAG
20 hyperelongation, and noting that Emoto and colleagues [29] have reported an increase in the expression of C4ST-1 in the vessels of a murine model of atherosclerosis, then we can speculate that these genes can be used as targets to assess the role of up regulation of these genes in atherosclerosis. Also our specific interest is the potential to inhibit the expression of these genes thus preventing GAG hyperelongation, lipid deposition and atherosclerosis an outcome we have previously reported for studies with imatinib [35] .
The signalling consequences of these studies are that the role of GPCR mediated transactivation of TGFBR1 extends from the general response of GAG hyperelongation to the specific responses of the expression of two individual genes and that concurrently the transactivation of the EGFR along with TGFBR1 explains all of the signalling in this model.
Our data showing that MMPs are not involved in PAR-1 to TGFBR1 transactivation indicates the mechanisms of PAR-1 transactivation of the EGFR and the TGFBR1 are mechanistically completely distinct [4, 16] . This presents a major challenge in terms of the discovery of a therapeutic target since there is no common target apparent. We have previously considered the efficacy of blocking the upstream GPCR and the implication for the efficacy of drugs such as Angiotensin receptor blockers but what of a specific target for blocking transactivation dependent signalling [44, 45] . There is one outstanding area that has been surprisingly little investigated in terms of its role on transactivation dependent signalling and that is the role G proteins and in the case of thrombin most likely the role of Gαq/11 [46, 47] .
A thorough investigation of the role of G protein in GPCR mediated transactivation signalling is warranted.
Conclusion
We have shown that PAR-1 mediated signalling leading to the expression of two genes for GAG synthesizing enzymes, whose expression correlates with the hyperelongation of GAG chains on biglycan, utilised only transactivation dependent signalling pathways involving the EGFR and TGFBR1. We have shown that the PAR-1 transactivation of TGFR1
does not involve MMPs and thus the transactivation pathways for the two receptors, insofar as they have been investigated are mechanistically distinct. In this model the need is to find a common mediator of transactivation dependent signalling and we proposed that the role of G proteins has not been adequately explored and should be done so in this context. In the context of cell biology the role of GPCR dependent transactivation of kinase receptors needs to be further explored to establish the breadth and full importance of this phenomenon.
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Figure 1:
Thrombin mediated mRNA expression of C4ST-1 and ChSy-1 is via the PAR-1 receptor. VSMCs were treated with thrombin (10 Units/ml) to investigate the effect on mRNA expression for A. C4ST-1 and B. ChSy-1. Cells were also treated in the presence and absence of PAR-1 antagonist SCH79797 (1-30µM) and then exposed to thrombin for 6 hours to assess the effect on mRNA expression of C. C4sT-1 and D. ChSy-1 Total RNA was harvested and the mRNA expression of C4ST-1 and ChSy-1 was analysed using RT-PCR. 18S was used as a house keeping gene. Results are expressed as the mean and standard error from three independent experiments. Statistical significance was determined by One-way ANOVA, followed by least significant difference post-hoc analysis, A,B * p < 0.05 and **, p < 0.01 basal versus thrombin C,D ##, p < 0.01 and #, p < 0.05 basal versus thrombin and **, p < 0.01 thrombin versus SCH79797 .
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Figure 2: Growth factors activating their respective receptors mediate mRNA expression of C4ST-1 and ChSy-1 which is inhibited by respective antagonists. VSMCs were pre-incubated with A-B. SCH79797 (30 μM), SB431542 (3 μM), AG1478 (5 μM) for 30 min and then exposed to thrombin (10 Units/ml) for 6 h. Total RNA was harvested and the mRNA expression of A. C4ST-1 and B. ChSy-1 were analysed using RT-PCR. 18s was used as a house keeping gene. Results are the mean and standard error from three separate experiments. Statistical significance was determined by One-way ANOVA, followed by least significant difference post-hoc analysis ##, p < 0.01 and #, p < 0.05 basal versus agonist (thrombin, TFG-β and EGF).
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Figure 3: Thrombin leads to the transactivation of protein serine/threonine and protein tyrosine kinase receptor signalling pathways in VSMCs. VSMCs were pre-incubated with A-B. SB431542 (0.1 -10 μM) or C-D. AG1478 (0.5-10 µM) for 30 min and then exposed to thrombin (10 Units/ml) for 6 h. SCH79797 (30 μM) was used as a control. Total RNA was harvested and the mRNA expression of C4ST-1 and ChSy-1 were analysed using RT-PCR. 18s was used as a house keeping gene. Results are the mean and standard error from three separate experiments. Statistical significance was determined by One-way ANOVA, followed by least significant difference post-hoc analysis ##, p < 0.01 basal versus thrombin and **, p < 0.01 and *, p < 0.05 thrombin versus antagonists (SB431542, AG1478 and SCH79797) was used for statistical analysis.
3A 3B
3C 3D Figure 4 : Thrombin via PAR-1 stimulated mRNA expression of C4ST-1 and ChSy-1 is mediated by cooperation of both protein serine/threonine and protein tyrosine kinase receptor signalling. VSMCs were pre-incubated with AG1478 (5 μM) , SB431542 (3 μM) or both for 30 min and then exposed to thrombin (10 Units/ml) or TRAP-STAL2 (100μM) for 6 h to determine the inhibitory effect for the mRNA expression of A,C C4ST-1 and D,F. ChSy-1. VSMCs were treated with thrombin (10Units/ml), EGF (100nM), TGF-β (2ng/ml) or both EGF and TGF-β for 6 hours to determine the combined activation for the mRNA expression of B.C4ST-1 and E.ChSy-1. Total RNA was harvested and the mRNA expression of C4ST-1 and ChSy-1 were analysed using RT-PCR. 18s was used as a house keeping gene. Data are expressed as the mean and standard error from three experiments. Statistical significance was determined by One-way ANOVA, followed by least significant difference post-hoc analysis A,C ##, p < 0.01 basal versus thrombin and *, p < 0.05 and **, p < 0.01 thrombin versus antagonist (AG1478 and SB431542) B,D **,p<0.01 basal versus agonist was used for statistical analysis.
